Santen Pharmaceutical Co., Ltd.
4536.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥541 | ¥562 | ¥484 | ¥558 |
| - Cash | ¥64 | ¥85 | ¥93 | ¥78 |
| + Debt | ¥36 | ¥35 | ¥34 | ¥32 |
| Enterprise Value | ¥513 | ¥513 | ¥425 | ¥512 |
| Revenue | ¥69 | ¥69 | ¥77 | ¥76 |
| % Growth | 0.6% | -11% | 1.1% | – |
| Gross Profit | ¥38 | ¥37 | ¥44 | ¥42 |
| % Margin | 54.7% | 54% | 56.6% | 55.3% |
| EBITDA | ¥15 | ¥12 | ¥19 | ¥16 |
| % Margin | 22.1% | 17.6% | 24.2% | 20.7% |
| Net Income | ¥8 | ¥6 | ¥9 | ¥9 |
| % Margin | 11.7% | 8.6% | 11.4% | 11.4% |
| EPS Diluted | 23.7 | 17.28 | 25.69 | 25.23 |
| % Growth | 37.2% | -32.7% | 1.8% | – |
| Operating Cash Flow | ¥6 | ¥8 | ¥19 | ¥14 |
| Capital Expenditures | -¥2 | -¥2 | -¥1 | -¥3 |
| Free Cash Flow | ¥4 | ¥6 | ¥18 | ¥11 |